Source:http://linkedlifedata.com/resource/pubmed/id/20047500
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2010-1-11
|
pubmed:abstractText |
BACKGROUND. Clinical management of human African trypanosomiasis requires patient follow-up of 2 years' duration. At each follow-up visit, cerebrospinal fluid (CSF) is examined for trypanosomes and white blood cells (WBCs). Shortening follow-up would improve patient comfort and facilitate control of human African trypanosomiasis. METHODS. A prospective study of 360 patients was performed in the Democratic Republic of the Congo. The primary outcomes of the study were cure, relapse, and death. The WBC count, immunoglobulin M level, and specific antibody levels in CSF samples were evaluated to detect treatment failure. The sensitivity and specificity of shortened follow-up algorithms were calculated. RESULTS. The treatment failure rate was 37%. Trypanosomes, a WBC count of > or = 100 cells/microL, and a LATEX/immunoglobulin M titer of 1:16 in CSF before treatment were risk factors for treatment failure, whereas human immunodeficiency virus infection status was not a risk factor. The following algorithm, which had 97.8% specificity and 94.4% sensitivity, is proposed for shortening the duration of follow-up: at 6 months, patients with trypanosomes or a WBC count of > or = 50 cells/microL in CSF are considered to have treatment failure, whereas patients with a CSF WBC count of > or = 5 cells/microL are considered to be cured and can discontinue follow-up. At 12 months, the remaining patients (those with a WBC count of > or = 6-49 cells/microL) need a test of cure, based on trypanosome presence and WBC count, applying a cutoff value of > or = 20 cells/microL. CONCLUSION. Combining criteria for failure and cure allows follow-up of patients with second-stage human African trypanosomiasis to be shortened to a maximum duration of 12 months.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1537-6613
|
pubmed:author |
pubmed-author:BüscherPhilippeP,
pubmed-author:BoelaertMarleenM,
pubmed-author:IlungaMédardM,
pubmed-author:LejonVeerleV,
pubmed-author:MentenJorisJ,
pubmed-author:MulundaJean PierreJP,
pubmed-author:Mumba NgoyiDieudonnéD,
pubmed-author:Muyembe TamfumJean JacquesJJ,
pubmed-author:PyanaPatiP,
pubmed-author:Van NieuwenhoveSimonS
|
pubmed:issnType |
Electronic
|
pubmed:day |
1
|
pubmed:volume |
201
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
453-63
|
pubmed:meshHeading |
pubmed-meshheading:20047500-Adult,
pubmed-meshheading:20047500-Algorithms,
pubmed-meshheading:20047500-Animals,
pubmed-meshheading:20047500-Antiprotozoal Agents,
pubmed-meshheading:20047500-Cerebrospinal Fluid,
pubmed-meshheading:20047500-Democratic Republic of the Congo,
pubmed-meshheading:20047500-Female,
pubmed-meshheading:20047500-Humans,
pubmed-meshheading:20047500-Leukocyte Count,
pubmed-meshheading:20047500-Male,
pubmed-meshheading:20047500-Risk Factors,
pubmed-meshheading:20047500-Sensitivity and Specificity,
pubmed-meshheading:20047500-Time Factors,
pubmed-meshheading:20047500-Trypanosoma brucei gambiense,
pubmed-meshheading:20047500-Trypanosomiasis, African,
pubmed-meshheading:20047500-Young Adult
|
pubmed:year |
2010
|
pubmed:articleTitle |
How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness.
|
pubmed:affiliation |
Department of Parasitology, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|